The life sciences sector is at a really critical crossroad. From pharmaceutical firms dealing with patent cliffs to biopharma groups racing to push new therapies into market, the pressure to innovate has just never been higher. And really, at the middle of all this shift sits artificial intelligence in life sciences — a tool that is changing, in practice, how research gets done, how drug candidates are built and tested, and how healthcare organisations manage sustainable growth.
From Bench to Boardroom: How One Geneticist is Quietly Reshaping the Future of Healthcare...
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Bret Bostwick from Breyer Capital about the rare path from genetics, clinical medicine and drug development into venture capital, and what that perspective reveals about the future of healthcare innovation.


Write a comment ...